AbbVie has acquired Nimble Therapeutics for $200 million, gaining access to an oral peptide drug candidate aimed at treating psoriasis by inhibiting the IL23 receptor. This addition complements AbbVie's existing injectable drug, Skyrizi, and aims to address significant unmet medical needs in autoimmune diseases.
AbbVie is set to acquire Nimble Therapeutics for $200 million, enhancing its pipeline of oral peptide drugs targeting immune diseases like psoriasis and inflammatory bowel disease. Nimble's lead candidate aims to inhibit IL-23, similar to AbbVie’s Skyrizi, but offers an oral delivery method. This acquisition marks AbbVie’s third buyout of an immune drug developer this year, reflecting a strategic push to strengthen its immunology portfolio.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
